Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15401384 | 0.74 | TAAR1 (0.39) | TAAR1KDM1ARCOR1CYP2A6 | |
| SCHEMBL15401382 | 0.74 | TAAR1 (0.39) | TAAR1KDM1ARCOR1CYP2A6 | |
| SCHEMBL2031283 | 0.74 | LMNA (0.40) | MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL10241861 | 0.74 | CYP2A6 (0.35) | TAAR1KDM1ARCOR1MEN1RAD52 | |
| SCHEMBL20910748 | 0.73 | — | — | |
| SCHEMBL2037798 | 0.73 | OPRM1 (0.35) | KMT2AALDH1A1 | |
| SCHEMBL991567 | 0.72 | CYP2A6 (0.42) | TAAR1KDM1ARCOR1CYP2A6ALDH1A1 | |
| SCHEMBL16699326 | 0.72 | KMT2A (0.37) | MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL20703425 | 0.70 | MEN1 (0.37) | MEN1KMT2AALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL5060581 | 0.70 | KDM1A (0.40) | KDM1ARCOR1CYP2A6ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221838-B2 | Inhibitors of AKT activity | ALMAC DISCOVERY LIMITED (IE) | 2015-12-29 | — | — | US | disclosed |
| EP-2516435-B1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-2516435-A1 | INHIBITORS OF AKT ACTIVITY | Almac Discovery Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077098-A9 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012027322-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011077098-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | TAAR1 4833/4885KDM1A 3400/4885RCOR1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.